IMPLANTATION OF THE THIRD GENERATION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (VENTAK PRx II) WITH THE SINGLE LEAD SYSTEM

Abstract

Seven VT/VF patients were safely implanted the 3rd generation implantable cardioverter defibrillator (I CD: Ventak PRxII) with the single lead (SL) system. 2 patients were used subcutaneous leads (array lead: AL) together. The mean defibrillation threshold was 15.0+/-3.5 J in the group using only SL and was not significantly different from that of the group using AL together (22.5+/-3.5J). However, the mean impedance at each defibrillation testing in the AL group was apparently lower (30.1+/-6.9ohms) than that of the SL group (46.9+/-4.0ohms)(p<0.05). We concluded that the AL using with the SL was useful to prevent a loss of defibrillation energy.